Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
This phase I trial studies the side effects and the best dose of veliparib and dinaciclib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment. Veliparib and dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase 1 Trial of ABT-888 and SCH727965 in Patients with Advanced Solid Tumors
- ClinicalTrials.gov Identifier: NCT01434316
- Protocol Number: 11-144
- Principal Investigator: Gerburg Wulf
- Principal Investigator: Central PIO
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required